| REC REF | IRAS NO | Full TITLE | Minimum No of Recruits Agreed | Maximum No. of Recruits Agreed | Date Agreed to Reach Target | Total No. Recruited at Target Date | Date Trial Closed to Recruitment | Total Recruitment to Trial |
|---|---|---|---|---|---|---|---|---|
| 13/LO/1252 | 135692 | The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum | 3 | 3 | 01/02/2016 | 3 | 01/07/2016 | 3 |
| 16/NW/0147 | 198056 | Odyssey DM- A Randomised, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidaemia at High Cardiovascular Risk with Non-HDL-C Not Adequately Controlled with Maximally Tolerated Statin Therapy | 4 | 4 | 01/10/2016 | 0 | 01/10/2016 | 0 |
| 13/NE/0269 | 134646 | TESARO: A Phase 3 Randomised Double blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer | 2 | 2 | 31/12/2015 | 2 | 30/09/2016 | 2 |
| 15/LO/1829 | 187483 | ROSACEA: Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety & Efficacy of Once-Daily CLS001 Topical Gel vs<br>Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week FU Period | 2 | 5 | 05/04/2016 | 3 | 26/10/2016 | 3 |
| 14/SC/0032 | 142458 | SPIRE 1 : B1481022 Phase 3 multi-center, double-blind, randomized, Placebo-controlled, parallel group evaluation of the Efficacy, safety, and tolerability of pf-04950615, in reducing the Occurrence of major cardiovascular events in high risk Subjects | 5 | 15 | 20/12/2015 | 15 | 22/07/2016 | 15 |
| 14/LO/2011 | 159926 | A prospective Randomised, open label, blinded endpoint (PROBE)study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation<br>(NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting<br>(RE-DUAL PCI) | 2 | 3 | 31/08/2016 | 4 | 31/10/2016 | 4 |